On June 15, 2021, Davidson Kempner European Partners, LLP announced that it has engaged with Qiagen N.V., the Executive Management, the Supervisory Board as well as many industry leaders and advisors. Davidson Kempner stated that following the failed Thermo Fisher Scientific sales process in August 2020, Davidson Kempner expressed Lawrence A. Rosen its view that in order for the Company to realise its potential and address historic issues with regards to the effectiveness of the Supervisory Board, there was a need to appoint a new external Chairman. Davidson Kempner expressed its view that appointing a new external Chairman with a strong executive healthcare background would go a long way in rebuilding trust and confidence, which will allow the Executive Management team's strong execution and improved performance and prospects to be properly reflected in the Company's valuation. Davidson Kempner stated that it intends to vote against the reappointment of Lawrence Rosen (Chairman) and Elizabeth E. Talett (Supervisory Board Director) at the upcoming annual general meeting of shareholders and Davidson Kempner encourages all shareholders to exercise their right and vote against Lawrence Rosen and Elizabeth E. Tallett.